Interfering with the Ubiquitin-Mediated Regulation of Akt as a Strategy for Cancer Treatment

Int J Mol Sci. 2023 Feb 1;24(3):2809. doi: 10.3390/ijms24032809.

Abstract

The serine/threonine kinase Akt modulates the functions of numerous substrates, many of them being involved in cell proliferation and growth, metabolism, angiogenesis, resistance to hypoxia and migration. Akt is frequently deregulated in many types of human cancers, its overexpression or abnormal activation being associated with the increased proliferation and survival of cancer cells. A promising avenue for turning off the functionality of Akt is to either interfere with the K63-linked ubiquitination that is necessary for Akt membrane recruitment and activation or increase the K48-linked polyubiquitination that aims to target Akt to the proteasome for its degradation. Recent evidence indicates that targeting the ubiquitin proteasome system is effective for certain cancer treatments. In this review, the functions and roles of Akt in human cancer will be discussed, with a main focus on molecules and compounds that target various elements of the ubiquitination processes that regulate the activation and inactivation of Akt. Moreover, their possible and attractive implications for cancer therapy will be discussed.

Keywords: Akt; cancer; ubiquitination.

Publication types

  • Review

MeSH terms

  • Humans
  • Neoplasms* / drug therapy
  • Proteasome Endopeptidase Complex / metabolism
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Ubiquitin* / metabolism
  • Ubiquitination

Substances

  • Ubiquitin
  • Proto-Oncogene Proteins c-akt
  • Proteasome Endopeptidase Complex
  • Protein Serine-Threonine Kinases

Grants and funding

This research received no external funding.